Tempus AI is expanding its clinical oncology offering with the launch of ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. ・The tool combines digital pathology and genomic ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today an update to the ArteraAI Prostate Test ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

To check for possible prostate cancer, physicians most often use prostate-specific antigen (PSA) tests and digital rectal exams (DREs). For a firm diagnosis, they use core needle biopsies. This page ...

Health-evidence reviewers reverse recommendation on a blood test that detects a biomarker of a common cancer after decades of ...

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic ...

New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for the disease ...

CHICAGO -- Patients with advanced prostate cancer treated with enzalutamide (Xtandi) had a significantly greater decline in ...